Literature DB >> 2410721

Prevention and reversal of tolerance to nitroglycerine with N-acetylcysteine.

J Torresi, J D Horowitz, G J Dusting.   

Abstract

A recent study demonstrated that the sulfhydryl donor N-acetylcysteine (NAC) potentiated hemodynamic responsiveness to nitroglycerine (NTG) in patients with ischaemic heart disease. The interaction between NTG and NAC in rings of bovine coronary artery was examined. Vasodilator responses to NTG were determined after elevation of tone with the thromboxane mimetic U46619 [(15S)-hydroxy-11 alpha, 9 alpha-(epoxymethano) prosta-5Z, 13E-dienoic acid]. NAC (1 microM-3 mM) induced no changes in tone of the preparation, but 10 microM NAC significantly potentiated responses to NTG (EC50 reduced from 0.69 +/- 0.19 microM to 0.22 +/- 0.06 microM; p less than 0.01). Increasing degrees of tolerance to NTG were produced at pH 7.4 by preincubating coronary rings with NTG in concentrations of 4.4 and 44 microM, and 0.22 mM. With 0.22 mM NTG, EC50 for subsequently administered NTG was increased to 11.0 +/- 1.8 microM (p less than 0.001 vs. control vessels). The degree of tolerance produced with this concentration of NTG was markedly attenuated by simultaneous (EC50 = 0.50 +/- 0.30 microM; p less than 0.001 vs. tolerant vessels) or subsequent (EC50 = 1.17 +/- 0.59 microM, p less than 0.001 vs. control vessels) incubation with 10 microM NAC. These data confirm that responses to NTG are modulated by sulfhydryl (or specifically cysteine) availability and suggest that in vitro tolerance to NTG is related to sulfhydryl (or cysteine) depletion. It is therefore possible that in vivo potentiation of NTG responses by NAC will be of clinical benefit in preventing or reversing loss of hemodynamic responsiveness to NTG.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410721     DOI: 10.1097/00005344-198507000-00024

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  19 in total

1.  Effects of N-acetylcysteine on nitroglycerin-induced relaxation and protein phosphorylation of porcine coronary arteries.

Authors:  Y Tate; K Kawasaki; S Ishibashi; U Ikeda; K Shimada
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

Review 2.  Mechanisms of nitrate tolerance: a review.

Authors:  R J Katz
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 3.  Causes and problems of nonresponse or poor response to drugs.

Authors:  P Salvà Lacombe; J A García Vicente; J Costa Pagès; P Lucio Morselli
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 4.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Nitrate tolerance. A problem during continuous nitrate administration.

Authors:  J O Parker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  The haemodynamic and anti-ischaemic effects of a single tablet of 80 mg isosorbide dinitrate in slow-release formulation and a review of nitrate tolerance.

Authors:  S Silber; A C Vogler; K H Krause; K Theisen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance.

Authors:  Nazish Sayed; David D Kim; Xavier Fioramonti; Toru Iwahashi; Walter N Durán; Annie Beuve
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

Review 8.  Nitrate tolerance. A review of the evidence.

Authors:  J T Flaherty
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 9.  Pharmacology of endothelium-derived nitric oxide and nitrovasodilators.

Authors:  L J Ignarro; G Ross; J Tillisch
Journal:  West J Med       Date:  1991-01

10.  Release of nitric oxide from glyceryl trinitrate by captopril but not enalaprilat: in vitro and in vivo studies.

Authors:  D Salvemini; A Pistelli; V Mollace
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.